Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (587)	3/10/2005 12:29:02 AM
From: Sam Citron	of 946

Wells Fargo "Fireside Chat" (3/1-2/05) Notes: "Xyotax, unlike Taxol, is a ten minute infusion instead of a three hour infusion" Bianco 4:10 "Because the side effect profile is dramatically different in the phase 1 2 effort, these patients wont have hair loss." Bianco 4:25 "Even if we dont meet primary endpoint ... we would argue to the Agency that the unmet medical need is a doublet therapy that you can dose aggressively to get improved survival for PS2s without increased toxicity as a consequence of it...It will be a win on neutropenia, sepsis, etc, and a win on QOL." Bianco ~ 44:00 One thing he kept repeating was that the test would validate that more is better. I guess what he meant was more cycles at lower dosages. Sam

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next